Autolus Therapeutics PLC Highlights Long-Term Success in Cancer Treatment Study

Autolus Therapeutics PLC, a London-based biopharmaceutical company specializing in cell therapies for cancer treatment, recently presented significant findings from the FELIX study at the 2025 European Hematology Association (EHA) Congress. The study focused on the long-term efficacy of Obe-Cel, a cell therapy developed by Autolus, in treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

The updated results from the FELIX study demonstrate Obe-Cel’s potential for long-term remission in patients with r/r B-ALL. With an extended median follow-up of 32.8 months, the study reported a median duration of response of 42.6 months. This duration is particularly impressive given the challenging nature of treating this patient population. Notably, 38.4% of responders achieved ongoing remission without the need for additional therapies, such as stem cell transplantation.

The study also highlighted the therapy’s durability, with over 50% of patients maintaining remission at the 24-month mark. The effectiveness of Obe-Cel was consistent across all age groups, including older adults, and no new safety concerns or Grade ≥3 secondary malignancies were observed during the extended follow-up period.

These findings suggest a potentially significant advancement in the treatment landscape for adult r/r B-ALL, offering hope for improved patient outcomes. The 24-month probability metrics further underscore the therapy’s impact, with 43% for Event-Free Survival and 46% for Overall Survival, indicating an emerging plateau in survival rates.

In addition to these promising results, Autolus Therapeutics PLC recently participated in a Goldman Sachs conference, where the company emphasized its strategic focus on the market introduction of Alcatsol, another therapeutic candidate in its pipeline.

As of June 10, 2025, Autolus Therapeutics PLC’s stock closed at $2.24 on the Nasdaq, with a market capitalization of approximately $601.48 million. Despite a challenging year, with a 52-week low of $1.105 in April 2025, the company’s recent developments may positively influence investor sentiment.

For more information on Autolus Therapeutics PLC and its innovative therapies, visit their website at www.autolus.com .